www.npr.org Open in urlscan Pro
2a02:26f0:3500:18::1724:a287  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Accessibility links
 * Skip to main content
 * Keyboard shortcuts for audio player

NPR 24 Hour Program StreamOn Air Now
 * Hourly News
 * Listen Live
 * Playlist

 * Open Navigation Menu
 * 
 * 
 * Newsletters
 * Sign In
 * NPR Shop
 * Donate

Close Navigation Menu
 * Home
 * News Expand/collapse submenu for News
   * National
   * World
   * Politics
   * Business
   * Health
   * Science
   * Climate
   * Race
 * Culture Expand/collapse submenu for Culture
   * Books
   * Movies
   * Television
   * Pop Culture
   * Food
   * Art & Design
   * Performing Arts
   * Life Kit
   * Gaming
 * Music Expand/collapse submenu for Music
   * Tiny Desk
   * Hip-Hop 50
   * All Songs Considered
   * Music Features
   * Live Sessions
 * Podcasts & Shows Expand/collapse submenu for Podcasts & Shows
   Daily
    * Morning Edition
    * Weekend Edition Saturday
    * Weekend Edition Sunday
    * All Things Considered
    * Fresh Air
    * Up First
   
   Featured
    * The NPR Politics Podcast
    * Throughline
    * Trump's Trials
    * Wild Card with Rachel Martin
   
    * More Podcasts & Shows

 * Search
 * Newsletters
 * Sign In
 * NPR Shop

 * 
 * Tiny Desk
 * Hip-Hop 50
 * All Songs Considered
 * Music Features
 * Live Sessions

 * About NPR
 * Diversity
 * Support
 * Careers
 * Press
 * Ethics

Cheap longevity drug? Researchers aim to test if metformin can slow down aging :
Shots - Health News Studies suggest people who take metformin for diabetes may
be at lower risk for cancer, heart disease and dementia. Now researchers aim to
test if it prevents age-related diseases in healthy people.


SHOTS

Health News From NPR
 * Your Health
 * Treatments & Tests
 * Health Inc.
 * Policy-ish
 * Public Health


 * Twitter


HOW TO THRIVE AS YOU AGE


A CHEAP DRUG MAY SLOW DOWN AGING. A STUDY WILL DETERMINE IF IT WORKS

April 22, 20245:01 AM ET
Heard on Morning Edition

Allison Aubrey

A CHEAP DRUG MAY SLOW DOWN AGING. A STUDY WILL DETERMINE IF IT WORKS

Listen· 6:216-Minute ListenPlaylist
Toggle more options
 * Download
 * Embed
   Embed <iframe src="https://www.npr.org/player/embed/1245872510/1246277665"
   width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded
   audio player">
 * Transcript

Enlarge this image

Venca-Stastny/Getty Images

Venca-Stastny/Getty Images

A drug taken by millions of people to control diabetes may do more than lower
blood sugar.

Research suggests metformin has anti-inflammatory effects that could help
protect against common age-related diseases including heart disease, cancer, and
cognitive decline.

Scientists who study the biology of aging have designed a clinical study, known
as The TAME Trial, to test whether metformin can help prevent these diseases and
promote a longer healthspan in healthy, older adults.

Michael Cantor, an attorney, and his wife Shari Cantor, the mayor of West
Hartford, Connecticut both take metformin. "I tell all my friends about it,"
Michael Cantor says. "We all want to live a little longer, high-quality life if
we can," he says.



Michael Cantor started on metformin about a decade ago when his weight and blood
sugar were creeping up. Shari Cantor began taking metformin during the pandemic
after she read that it may help protect against serious infections.

Enlarge this image

Shari and Michael Cantor both take metformin. They are both in their mid-60s and
say they feel healthy and full of energy. Theresa Oberst/Michael Cantor hide
caption

toggle caption
Theresa Oberst/Michael Cantor


Shari and Michael Cantor both take metformin. They are both in their mid-60s and
say they feel healthy and full of energy.

Theresa Oberst/Michael Cantor

The Cantors are in their mid-60s and both say they feel healthy and have lots of
energy. Both noticed improvements in their digestive systems – feeling more
"regular" after they started on the drug,

Metformin costs less than a dollar a day, and depending on insurance, many
people pay no out-of-pocket costs for the drug.

"I don't know if metformin increases lifespan in people, but the evidence that
exists suggests that it very well might," says Steven Austad, a senior
scientific advisor at the American Federation for Aging Research who studies the
biology of aging.


AN OLD DRUG WITH SURPRISING BENEFITS

Metformin was first used to treat diabetes in the 1950s in France. The drug is a
derivative of guanidine, a compound found in Goat's Rue, an herbal medicine long
used in Europe.

The FDA approved metformin for the treatment of type 2 diabetes in the U.S. in
the 1990s. Since then, researchers have documented several surprises, including
a reduced risk of cancer. "That was a bit of a shock," Austad says. A
meta-analysis that included data from dozens of studies, found people who took
metformin had a lower risk of several types of cancers, including
gastrointestinal, urologic and blood cancers.



Austad also points to a British study that found a lower risk of dementia and
mild cognitive decline among people with type 2 diabetes taking metformin. In
addition, there's research pointing to improved cardiovascular outcomes in
people who take metformin including a reduced risk of cardiovascular death.

As promising as this sounds, Austad says most of the evidence is observational,
pointing only to an association between metformin and the reduced risk. The
evidence stops short of proving cause and effect. Also, it's unknown if the
benefits documented in people with diabetes will also reduce the risk of
age-related diseases in healthy, older adults.

"That's what we need to figure out," says Steve Kritchevsky, a professor of
gerontology at Wake Forest School of Medicine, who is a lead investigator for
the Tame Trial.

The goal is to better understand the mechanisms and pathways by which metformin
works in the body. For instance, researchers are looking at how the drug may
help improve energy in the cells by stimulating autophagy, which is the process
of clearing out or recycling damaged bits inside cells.


SHOTS - HEALTH NEWS


SCIENTISTS CAN TELL HOW FAST YOU'RE AGING. NOW, THE TRICK IS TO SLOW IT DOWN


SHOTS - HEALTH NEWS


YOU CAN ORDER A TEST TO FIND OUT YOUR BIOLOGICAL AGE. IS IT WORTH IT?

Researchers also want to know more about how metformin can help reduce
inflammation and oxidative stress, which may slow biological aging.

"When there's an excess of oxidative stress, it will damage the cell. And that
accumulation of damage is essentially what aging is," Kritchevsky explains.

When the forces that are damaging cells are running faster than the forces that
are repairing or replacing cells, that's aging, Kritchevsky says. And it's
possible that drugs like metformin could slow this process down.

By targeting the biology of aging, the hope is to prevent or delay multiple
diseases, says Dr. Nir Barzilai of Albert Einstein College of Medicine, who
leads the effort to get the trial started.


THE ULTIMATE IN PREVENTATIVE MEDICINE

Back in 2015, Austad and a bunch of aging researchers began pushing for a
clinical trial.



"A bunch of us went to the FDA to ask them to approve a trial for metformin,'
Austad recalls, and the agency was receptive. "If you could help prevent
multiple problems at the same time, like we think metformin may do, then that's
almost the ultimate in preventative medicine," Austad says.

The aim is to enroll 3,000 people between the ages of 65 and 79 for a six-year
trial. But Dr. Barzilai says it's been slow going to get it funded. "The main
obstacle with funding this study is that metformin is a generic drug, so no
pharmaceutical company is standing to make money," he says.

Barzilai has turned to philanthropists and foundations, and has some pledges.
The National Institute on Aging, part of the National Institutes of Health, set
aside about $5 million for the research, but that's not enough to pay for the
study which is estimated to cost between $45 and $70 million.

The frustration over the lack of funding is that if the trial points to
protective effects, millions of people could benefit. "It's something that
everybody will be able to afford," Barzilai says.

Currently the FDA doesn't recognize aging as a disease to treat, but the
researchers hope this would usher in a paradigm shift — from treating each
age-related medical condition separately, to treating these conditions together,
by targeting aging itself.

For now, metformin is only approved to treat type 2 diabetes in the U.S., but
doctors can prescribe it off-label for conditions other than its approved use.

Michael and Shari Cantor's doctors were comfortable prescribing it to them,
given the drug's long history of safety and the possible benefits in delaying
age-related disease.

"I walk a lot, I hike, and at 65 I have a lot of energy," Michael Cantor says. I
feel like the metformin helps," he says. He and Shari say they have not
experienced any negative side effects.



Research shows a small percentage of people who take metformin experience GI
distress that makes the drug intolerable. And, some people develop a b12 vitamin
deficiency. One study found people over the age of 65 who take metformin may
have a harder time building new muscle.


SHOTS - HEALTH NEWS


MILLIONS OF WOMEN ARE 'UNDER-MUSCLED.' THESE FOODS HELP BUILD STRENGTH

"There's some evidence that people who exercise who are on metformin have less
gain in muscle mass, says Dr. Eric Verdin, President of the Buck Institute for
Research on Aging. That could be a concern for people who are under-muscled.

But Verdin says it may be possible to repurpose metformin in other ways "There
are a number of companies that are exploring metformin in combination with other
drugs," he says. He points to research underway to combine metformin with a drug
called galantamine for the treatment of sarcopenia, which is the medical term
for age-related muscle loss. Sarcopenia affects millions of older people,
especially women.

The science of testing drugs to target aging is rapidly advancing, and metformin
isn't the only medicine that may treat the underlying biology.

"Nobody thinks this is the be all and end all of drugs that target aging,"
Austad says. He says data from the clinical trial could stimulate investment by
the big pharmaceutical companies in this area. "They may come up with much
better drugs," he says.

Michael Cantor knows there's no guarantee with metformin. "Maybe it doesn't do
what we think it does in terms of longevity, but it's certainly not going to do
me any harm," he says.

Cantor's father had his first heart attack at 51. He says he wants to do all he
can to prevent disease and live a healthy life, and he thinks Metformin is one
tool that may help.

For now, Dr. Barzilai says the metformin clinical trial can get underway when
the money comes in.


SHOTS - HEALTH NEWS


7 HABITS TO LIVE A HEALTHIER LIFE, INSPIRED BY THE WORLD'S LONGEST-LIVED
COMMUNITIES

This story was edited by Jane Greenhalgh

 * metformin
 * longevity
 * Aging

 * Facebook
 * Flipboard
 * Email






MORE STORIES FROM NPR

SHOTS - HEALTH NEWS

WANT TO PROTECT YOUR KIDS' EYES FROM MYOPIA? GET THEM TO PLAY OUTSIDE

SHOTS - HEALTH NEWS

A TRIBE IN MAINE IS USING OPIOID SETTLEMENT FUNDS ON A SWEAT LODGE TO TREAT
ADDICTION

SHOTS - HEALTH NEWS

WHY WRITING BY HAND BEATS TYPING FOR THINKING AND LEARNING

SHOTS - HEALTH NEWS

THEIR FIRST BABY CAME WITH MEDICAL DEBT. THESE ILLINOIS PARENTS WON'T HAVE
ANOTHER.

SHOTS - HEALTH NEWS

MEDICAL RESIDENTS ARE STARTING TO AVOID STATES WITH ABORTION BANS, DATA SHOWS

SHOTS - HEALTH NEWS

DECADES-OLD LAW LIMITS ACCESS TO WEGOVY FOR MEDICAID BENEFICIARIES


POPULAR ON NPR.ORG

SPACE

THERE'S STILL A CHANCE TO SEE THE NORTHERN LIGHTS FROM LOWER LATITUDES

SCIENCE

THE FIRST PERSON TO RECEIVE A GENETICALLY MODIFIED PIG KIDNEY TRANSPLANT HAS
DIED

OBITUARIES

ROGER CORMAN, THE B-MOVIE LEGEND WHO LAUNCHED A-LIST CAREERS, DIES AT 98

SPACE

THE HUGE SOLAR STORM IS KEEPING POWER GRID AND SATELLITE OPERATORS ON EDGE

BUSINESS

WITH 'BLEISURE' AND FEWER WORKERS, THE AMERICAN HOTEL IS IN RECOVERY

NATIONAL

CONTROLLED DEMOLITION PLANNED AT BALTIMORE BRIDGE COLLAPSE SITE


NPR EDITORS' PICKS

MIDDLE EAST

WHAT TO KNOW ABOUT MOHAMMAD MOKHBER, WHO IS STEPPING IN AS INTERIM PRESIDENT OF
IRAN

AFRICA

JACOB ZUMA BANNED FROM RUNNING IN SOUTH AFRICA'S ELECTION

LAW

TRUMP'S NEW YORK CRIMINAL HUSH MONEY TRIAL CONTINUES INTO A FIFTH WEEK OF
TESTIMONY

GOATS AND SODA

A NEW PILL CURES PRESCHOOLERS OF A PARASITIC WORM. DELIVERING IT COULD BE A
CHALLENGE

WORLD

JULIAN ASSANGE CAN APPEAL HIS EXTRADITION TO THE U.S., A BRITISH COURT HAS RULED

ALL SONGS CONSIDERED

LISTENER POLL: WHAT SONG REMINDS YOU OF LEAVING HIGH SCHOOL?


SHOTS

Health News From NPR

READ & LISTEN

 * Home
 * News
 * Culture
 * Music
 * Podcasts & Shows

CONNECT

 * Newsletters
 * Facebook
 * Instagram
 * Press
 * Public Editor
 * Corrections
 * Contact & Help

ABOUT NPR

 * Overview
 * Diversity
 * NPR Network
 * Accessibility
 * Ethics
 * Finances

GET INVOLVED

 * Support Public Radio
 * Sponsor NPR
 * NPR Careers
 * NPR Shop
 * NPR Events
 * NPR Extra

 * Terms of Use
 * Privacy
 * Your Privacy Choices
 * Text Only
 * © 2024 npr




Sponsor Message

Become an NPR sponsor





COOKIE CONSENT & SPONSORSHIP CHOICES

We and our 169 partners store and/or access information on a device, such as
unique IDs in cookies to process personal data. You may accept or manage your
choices by clicking below, including your right to object where legitimate
interest is used, or at any time in the privacy policy page. These choices will
be signaled to our partners and will not affect browsing data.
By clicking “Accept All,” you agree to the use of cookies, similar tracking and
storage technologies, and information about your device to enhance your viewing,
listening and user experience, personalize content, personalize messages from
NPR’s sponsors, provide social media features, and analyze NPR’s traffic. This
information is shared with social media, sponsorship, analytics, and other
vendors or service providers.


WE AND OUR PARTNERS PROCESS DATA TO PROVIDE:

Actively scan device characteristics for identification. Store and/or access
information on a device. Personalised advertising and content, advertising and
content measurement, audience research and services development. List of
Partners (service providers or vendors)

Reject All Accept All
Manage Preferences



Your Opt Out Preference Signal is Honored


MANAGE PREFERENCES

We process your data to deliver content or advertisements and measure the
delivery of such content or advertisements to extract insights about our
website. We share this information with our partners on the basis of consent and
legitimate interest. You may exercise your right to consent or object to a
legitimate interest, based on a specific purpose below or at a partner level in
the link under each purpose. These choices will be signaled to our vendors
participating in the Transparency and Consent Framework.
User ID: 9043972e-7110-4f95-bc51-8e0f73efc9e0
Accept All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY OR ESSENTIAL COOKIES

Always Active

These cookies are essential to provide you with services available through the
NPR Services and to enable you to use some of their features. For example, these
cookies allow NPR to remember your registration information while you are logged
in. Local station customization, the NPR Shop, and other interactive features
also use cookies. Without these cookies, the services that you have asked for
cannot be provided, and we only use these cookies to provide you with those
services.

Cookies Details‎

PERFORMANCE AND ANALYTICS COOKIES

Performance and Analytics Cookies

These cookies are used to collect information about traffic to our Services and
how users interact with the NPR Services. The information collected includes the
number of visitors to the NPR Services, the websites that referred visitors to
the NPR Services, the pages that they visited on the NPR Services, what time of
day they visited the NPR Services, whether they have visited the NPR Services
before, and other similar information. We use this information to help operate
the NPR Services more efficiently, to gather broad demographic information and
to monitor the level of activity on the NPR Services.

Cookies Details‎

FUNCTIONAL COOKIES

Functional Cookies

These cookies allow our Services to remember choices you make when you use them,
such as remembering your Member station preferences and remembering your account
details. The purpose of these cookies is to provide you with a more personal
experience and to prevent you from having to re-enter your preferences every
time you visit the NPR Services.

Cookies Details‎

TARGETING AND SPONSOR COOKIES

Targeting and Sponsor Cookies

These cookies track your browsing habits or other information, such as location,
to enable us to show sponsorship credits which are more likely to be of interest
to you. These cookies use information about your browsing history to group you
with other users who have similar interests. Based on that information, and with
our permission, we and our sponsors can place cookies to enable us or our
sponsors to show sponsorship credits and other messages that we think will be
relevant to your interests while you are using third-party services.

Cookies Details‎

STORE AND/OR ACCESS INFORMATION ON A DEVICE 117 PARTNERS CAN USE THIS PURPOSE

Store and/or access information on a device

Cookies, device or similar online identifiers (e.g. login-based identifiers,
randomly assigned identifiers, network based identifiers) together with other
information (e.g. browser type and information, language, screen size, supported
technologies etc.) can be stored or read on your device to recognise it each
time it connects to an app or to a website, for one or several of the purposes
presented here.

List of IAB Vendors‎ | View Illustrations 

PERSONALISED ADVERTISING AND CONTENT, ADVERTISING AND CONTENT MEASUREMENT,
AUDIENCE RESEARCH AND SERVICES DEVELOPMENT 153 PARTNERS CAN USE THIS PURPOSE

Personalised advertising and content, advertising and content measurement,
audience research and services development

 * USE LIMITED DATA TO SELECT ADVERTISING 107 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Advertising presented to you on this service can be based on limited data,
   such as the website or app you are using, your non-precise location, your
   device type or which content you are (or have been) interacting with (for
   example, to limit the number of times an ad is presented to you).
   
   View Illustrations 
   Object to Legitimate Interests Remove Objection

 * CREATE PROFILES FOR PERSONALISED ADVERTISING 81 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Information about your activity on this service (such as forms you submit,
   content you look at) can be stored and combined with other information about
   you (for example, information from your previous activity on this service and
   other websites or apps) or similar users. This is then used to build or
   improve a profile about you (that might include possible interests and
   personal aspects). Your profile can be used (also later) to present
   advertising that appears more relevant based on your possible interests by
   this and other entities.
   
   View Illustrations 

 * USE PROFILES TO SELECT PERSONALISED ADVERTISING 79 PARTNERS CAN USE THIS
   PURPOSE
   
   Switch Label
   
   Advertising presented to you on this service can be based on your advertising
   profiles, which can reflect your activity on this service or other websites
   or apps (like the forms you submit, content you look at), possible interests
   and personal aspects.
   
   View Illustrations 

 * CREATE PROFILES TO PERSONALISE CONTENT 44 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Information about your activity on this service (for instance, forms you
   submit, non-advertising content you look at) can be stored and combined with
   other information about you (such as your previous activity on this service
   or other websites or apps) or similar users. This is then used to build or
   improve a profile about you (which might for example include possible
   interests and personal aspects). Your profile can be used (also later) to
   present content that appears more relevant based on your possible interests,
   such as by adapting the order in which content is shown to you, so that it is
   even easier for you to find content that matches your interests.
   
   View Illustrations 

 * USE PROFILES TO SELECT PERSONALISED CONTENT 35 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Content presented to you on this service can be based on your content
   personalisation profiles, which can reflect your activity on this or other
   services (for instance, the forms you submit, content you look at), possible
   interests and personal aspects, such as by adapting the order in which
   content is shown to you, so that it is even easier for you to find
   (non-advertising) content that matches your interests.
   
   View Illustrations 

 * MEASURE ADVERTISING PERFORMANCE 140 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Information regarding which advertising is presented to you and how you
   interact with it can be used to determine how well an advert has worked for
   you or other users and whether the goals of the advertising were reached. For
   instance, whether you saw an ad, whether you clicked on it, whether it led
   you to buy a product or visit a website, etc. This is very helpful to
   understand the relevance of advertising campaigns.
   
   View Illustrations 
   Object to Legitimate Interests Remove Objection

 * MEASURE CONTENT PERFORMANCE 70 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Information regarding which content is presented to you and how you interact
   with it can be used to determine whether the (non-advertising) content e.g.
   reached its intended audience and matched your interests. For instance,
   whether you read an article, watch a video, listen to a podcast or look at a
   product description, how long you spent on this service and the web pages you
   visit etc. This is very helpful to understand the relevance of
   (non-advertising) content that is shown to you.
   
   View Illustrations 
   Object to Legitimate Interests Remove Objection

 * UNDERSTAND AUDIENCES THROUGH STATISTICS OR COMBINATIONS OF DATA FROM
   DIFFERENT SOURCES 81 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Reports can be generated based on the combination of data sets (like user
   profiles, statistics, market research, analytics data) regarding your
   interactions and those of other users with advertising or (non-advertising)
   content to identify common characteristics (for instance, to determine which
   target audiences are more receptive to an ad campaign or to certain
   contents).
   
   View Illustrations 
   Object to Legitimate Interests Remove Objection

 * DEVELOP AND IMPROVE SERVICES 108 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Information about your activity on this service, such as your interaction
   with ads or content, can be very helpful to improve products and services and
   to build new products and services based on user interactions, the type of
   audience, etc. This specific purpose does not include the development or
   improvement of user profiles and identifiers.
   
   View Illustrations 
   Object to Legitimate Interests Remove Objection

 * USE LIMITED DATA TO SELECT CONTENT 32 PARTNERS CAN USE THIS PURPOSE
   
   Switch Label
   
   Content presented to you on this service can be based on limited data, such
   as the website or app you are using, your non-precise location, your device
   type, or which content you are (or have been) interacting with (for example,
   to limit the number of times a video or an article is presented to you).
   
   View Illustrations 
   Object to Legitimate Interests Remove Objection

List of IAB Vendors‎

ACTIVELY SCAN DEVICE CHARACTERISTICS FOR IDENTIFICATION 26 PARTNERS CAN USE THIS
PURPOSE

Actively scan device characteristics for identification

With your acceptance, certain characteristics specific to your device might be
requested and used to distinguish it from other devices (such as the installed
fonts or plugins, the resolution of your screen) in support of the purposes
explained in this notice.

List of IAB Vendors‎

ENSURE SECURITY, PREVENT AND DETECT FRAUD, AND FIX ERRORS 106 PARTNERS CAN USE
THIS PURPOSE

Always Active

Your data can be used to monitor for and prevent unusual and possibly fraudulent
activity (for example, regarding advertising, ad clicks by bots), and ensure
systems and processes work properly and securely. It can also be used to correct
any problems you, the publisher or the advertiser may encounter in the delivery
of content and ads and in your interaction with them.

List of IAB Vendors‎ | View Illustrations 

DELIVER AND PRESENT ADVERTISING AND CONTENT 100 PARTNERS CAN USE THIS PURPOSE

Always Active

Certain information (like an IP address or device capabilities) is used to
ensure the technical compatibility of the content or advertising, and to
facilitate the transmission of the content or ad to your device.

List of IAB Vendors‎ | View Illustrations 

MATCH AND COMBINE DATA FROM OTHER DATA SOURCES 80 PARTNERS CAN USE THIS PURPOSE

Always Active

Information about your activity on this service may be matched and combined with
other information relating to you and originating from various sources (for
instance your activity on a separate online service, your use of a loyalty card
in-store, or your answers to a survey), in support of the purposes explained in
this notice.

List of IAB Vendors‎

LINK DIFFERENT DEVICES 61 PARTNERS CAN USE THIS PURPOSE

Always Active

In support of the purposes explained in this notice, your device might be
considered as likely linked to other devices that belong to you or your
household (for instance because you are logged in to the same service on both
your phone and your computer, or because you may use the same Internet
connection on both devices).

List of IAB Vendors‎

IDENTIFY DEVICES BASED ON INFORMATION TRANSMITTED AUTOMATICALLY 100 PARTNERS CAN
USE THIS PURPOSE

Always Active

Your device might be distinguished from other devices based on information it
automatically sends when accessing the Internet (for instance, the IP address of
your Internet connection or the type of browser you are using) in support of the
purposes exposed in this notice.

List of IAB Vendors‎
Back Button


COOKIE LIST



Search Icon
Filter Icon

Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label

Reject All Confirm My Choices